Avaliação da qualidade de vida em pacientes após ressecção de sarcoma de partes moles
Carregando...
Tipo
TCC
Data de publicação
2024-06-20
Periódico
Citações (Scopus)
Autores
Zanolla, Pedro Schnaider
Orientador
Campos, Eurico Cleto Ribeiro de
Título da Revista
ISSN da Revista
Título de Volume
Membros da banca
Programa
Resumo
Objetivos: Avaliar a qualidade de vida em pacientes que passaram por ressecção de sarcoma de partes moles utilizando o protocolo EORTC QLQ 30 (European Organization for Research and Treatment of Cancer). Metodologia: O estudo transversal avaliou a qualidade de vida de pacientes com sarcoma de partes moles usando o questionário EORTC QLQ-C30 e análises estatísticas detalhadas de dados sociodemográficos e clínicos. Resultados: A amostra consiste em 22 pacientes com idade média de 46,86 anos, sendo 45,5% homens e 54,5% mulheres. A maioria apresenta estadiamento T2 (45,5%), N2 (95,5%) e M2, com estadiamento predominante em EC III (50,0%). Metade são ASA II (50,0%) e 59,1% são ECOG 0. Cinquenta por cento dos pacientes têm duas comorbidades, 18,2% apresentaram recorrência do sarcoma e 90,9% receberam tratamento de intensidade 1. Após a ressecção do tumor, relataram boa qualidade de vida geral e funcional, com sintomas menos pronunciados. Houve correlação negativa entre idade, múltiplas comorbidades e qualidade de vida. Pacientes com T2 tiveram qualidade de vida menor que T1 (p = 0,049) e T2 (p = 0,02), e pacientes ASA I tiveram melhor qualidade de vida que ASA II (p = 0,033) e ASA III (p = 0,031). ECOG 0 foi associado a melhor qualidade de vida que ECOG I (p = 0,0058), e pacientes EC I tiveram melhor qualidade de vida que EC II (p = 0,032), destacando a importância do estadiamento na qualidade de vida. Conclusão: O estudo revelou que a qualidade de vida de pacientes com sarcoma de partes moles após ressecção tumoral é significativamente influenciada pelo tamanho do tumor, estado de saúde geral, funcionalidade e estadiamento, enfatizando a necessidade de uma abordagem multidimensional e intervenções personalizadas para otimizar a qualidade de vida desses pacientes.
Objectives: To assess the quality of life in patients who underwent resection of soft tissue sarcoma using the EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer) protocol. Methodology: The cross-sectional study assessed the quality of life of patients with soft tissue sarcoma using the EORTC QLQ-C30 questionnaire and detailed statistical analyses of sociodemographic and clinical data. Results: The sample consists of 22 patients with a mean age of 46.86 years, with 45.5% men and 54.5% women. Most patients present with T2 (45.5%), N2 (95.5%), and M2 staging, with a predominant stage of EC III (50.0%). Half are classified as ASA II (50.0%) and 59.1% are ECOG 0. Fifty percent of the patients have two comorbidities, 18.2% had sarcoma recurrence, and 90.9% received intensity level 1 treatment. After tumor resection, patients reported good overall and functional quality of life, with less pronounced symptoms. There was a negative correlation between age, multiple comorbidities, and quality of life. Patients with T2 had lower quality of life than T1 (p = 0.049) and T2 (p = 0.02), and ASA I patients had better quality of life than ASA II (p = 0.033) and ASA III (p = 0.031). ECOG 0 was associated with better quality of life than ECOG I (p = 0.0058), and EC I patients had better quality of life than EC II (p = 0.032), highlighting the importance of staging in quality of life. Conclusion: The study revealed that the quality of life of patients with soft tissue sarcoma after tumor resection is significantly influenced by tumor size, general health status, functionality, and staging, emphasizing the need for a multidimensional approach and personalized interventions to optimize these patients' quality of life.
Objectives: To assess the quality of life in patients who underwent resection of soft tissue sarcoma using the EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer) protocol. Methodology: The cross-sectional study assessed the quality of life of patients with soft tissue sarcoma using the EORTC QLQ-C30 questionnaire and detailed statistical analyses of sociodemographic and clinical data. Results: The sample consists of 22 patients with a mean age of 46.86 years, with 45.5% men and 54.5% women. Most patients present with T2 (45.5%), N2 (95.5%), and M2 staging, with a predominant stage of EC III (50.0%). Half are classified as ASA II (50.0%) and 59.1% are ECOG 0. Fifty percent of the patients have two comorbidities, 18.2% had sarcoma recurrence, and 90.9% received intensity level 1 treatment. After tumor resection, patients reported good overall and functional quality of life, with less pronounced symptoms. There was a negative correlation between age, multiple comorbidities, and quality of life. Patients with T2 had lower quality of life than T1 (p = 0.049) and T2 (p = 0.02), and ASA I patients had better quality of life than ASA II (p = 0.033) and ASA III (p = 0.031). ECOG 0 was associated with better quality of life than ECOG I (p = 0.0058), and EC I patients had better quality of life than EC II (p = 0.032), highlighting the importance of staging in quality of life. Conclusion: The study revealed that the quality of life of patients with soft tissue sarcoma after tumor resection is significantly influenced by tumor size, general health status, functionality, and staging, emphasizing the need for a multidimensional approach and personalized interventions to optimize these patients' quality of life.
Descrição
Palavras-chave
câncer , EORTC QLQ 30 , qualidade de vida , sarcoma de partes moles , cancer , EORTC QLQ-C30 , quality of life , soft tissue sarcoma